Company / Capital Returned to Shareholders
Bristol Myers Squibb Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$5.0B
FY2025
5-year range
$4.9B / $10.7B
FY2021-FY2025
Trend
+3.7%
vs FY2024
Sector context
#7 of 52
Health Care
What the data says
Bristol Myers Squibb's capital returned to shareholders of $5.0B is higher than 87% of companies in the Health Care sector (FY2025). Capital Returned to Shareholders has fluctuated over the past 10 years, ranging from $2.6B in FY2016 to $10.7B in FY2023.
Based on SEC 10-K filings.
$5.0B in FY2025 with a 5-year CAGR of -2.1%. Top quartile in the Health Care sector.
Declined from $10.7B to $5.0B over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -3.5%
- 5-Year CAGR
- -2.1%
- 10-Year CAGR
- -
Sector benchmark
+278.0% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.1%, indicating a declining trend.
- In FY2025, capital returned to shareholders increased 3.7% year-over-year.
- Ranks #7 out of 52 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2023.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.0B | +3.7% |
| FY2024 | $4.9B | -54.5% |
| FY2023 | $10.7B | +90.1% |
| FY2022 | $5.6B | -43.7% |
| FY2021 | $10.0B | +77.5% |
| FY2020 | $5.6B | +11.4% |
| FY2019 | $5.0B | +81.6% |
| FY2018 | $2.8B | -44.9% |
| FY2017 | $5.0B | +91.9% |
| FY2016 | $2.6B | -4.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026